[go: up one dir, main page]

NO20072806L - Aryloksy-substituerte benzimidazolderivater - Google Patents

Aryloksy-substituerte benzimidazolderivater

Info

Publication number
NO20072806L
NO20072806L NO20072806A NO20072806A NO20072806L NO 20072806 L NO20072806 L NO 20072806L NO 20072806 A NO20072806 A NO 20072806A NO 20072806 A NO20072806 A NO 20072806A NO 20072806 L NO20072806 L NO 20072806L
Authority
NO
Norway
Prior art keywords
nitrogen
hydrogen
integer
carbon
aryloxy
Prior art date
Application number
NO20072806A
Other languages
English (en)
Inventor
Fumiko Sakai
Teruyuki Nishimura
Jun-Ichi Eiki
Noriaki Hashimoto
Keiji Takahashi
Chisato Nakama
Yoshio Ogino
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of NO20072806L publication Critical patent/NO20072806L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser med generell formel (I) eller farmasøytisk akseptable salter av disse, har glukokinaseaktiverende aktivitet og er anvendelige som terapeutiske midler for diabetes og fedme. I formel (I) er R1 og R2 hydrogen; R3 er hydrogen eller halogen; R4 er hydrogen eller lavere alkyl; Q er karbon, nitrogen eller svovel (forutsatt at svovelatomet kan være mono- eller disubstituert med okso); R5 og R6 er hydrogen eller lavere alkyl; X1, X2, X3 og X4 er uavhengig av hverandre karbon eller nitrogen; Z er oksygen, svovel eller nitrogen; Ar er aryl- eller heteroaryl; A er en 5- eller 6-leddet, nitrogenholdig, aromatisk, heterosyklisk gruppe; m er et helt tall fra 1 til 6; n er et helt tall fra 0 til 3; p er et helt tall fra 0 til 2 (forutsatt at minst to av X1-X4 er karbon); og q er 0 eller 1.
NO20072806A 2004-11-02 2007-06-01 Aryloksy-substituerte benzimidazolderivater NO20072806L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004319339 2004-11-02
JP2005178628 2005-06-17
PCT/JP2005/020483 WO2006049304A1 (ja) 2004-11-02 2005-11-01 アリールオキシ置換ベンズイミダゾール誘導体

Publications (1)

Publication Number Publication Date
NO20072806L true NO20072806L (no) 2007-07-27

Family

ID=36319300

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072806A NO20072806L (no) 2004-11-02 2007-06-01 Aryloksy-substituerte benzimidazolderivater

Country Status (17)

Country Link
US (1) US7932394B2 (no)
EP (1) EP1810969B1 (no)
JP (1) JP5036316B2 (no)
KR (1) KR20070083939A (no)
CN (1) CN101094847B (no)
AU (1) AU2005301608B2 (no)
BR (1) BRPI0517232A (no)
CA (1) CA2586056C (no)
CR (1) CR9078A (no)
EC (1) ECSP077422A (no)
IL (1) IL182679A0 (no)
MA (1) MA29043B1 (no)
MX (1) MX2007005289A (no)
NO (1) NO20072806L (no)
NZ (1) NZ554440A (no)
RU (1) RU2398773C2 (no)
WO (1) WO2006049304A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728025B2 (en) * 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
WO2007007910A1 (ja) 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. ヘテロ環置換ベンズイミダゾール誘導体
ES2380683T3 (es) * 2005-12-15 2012-05-17 Astrazeneca Ab Difenil-éteres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
EP2188274A4 (en) * 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
WO2009063821A1 (ja) 2007-11-12 2009-05-22 Banyu Pharmaceutical Co., Ltd. ヘテロアリールオキシキナゾリン誘導体
NZ585370A (en) 2007-12-19 2012-09-28 Boehringer Ingelheim Int Viral polymerase inhibitors
US20100267708A1 (en) 2007-12-20 2010-10-21 Lg Life Sciences Ltd. Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
AU2009280579A1 (en) 2008-08-15 2010-02-18 Banyu Pharmaceutical Co.,Ltd. Acetyl pyrrolidinyl indole derivative
CA2734981A1 (en) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co., Ltd. Oxotetrahydrofuran-2-yl-benzimidazole derivative
CN101607923B (zh) * 2009-07-21 2012-12-19 焦宁 芳基腈类化合物或其衍生物及其合成方法和应用
CN103502244B (zh) * 2010-11-09 2014-10-08 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
US20120258891A1 (en) 2011-04-07 2012-10-11 Nimblegen Systems Gmbh Diarylsulfide backbone containing photolabile protecting groups
WO2015161016A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Bicyclic cgrp receptor antagonists
TWI679198B (zh) * 2015-11-17 2019-12-11 美商陶氏益農有限責任公司 製備４-（（６-（２-（２，４-二氟苯基）-１，１-二氟-２-羥基-３-（１ｈ-１，２，４-三唑-１-基）丙基）吡啶-３-基）氧基）苄腈之方法
US20180327359A1 (en) * 2015-11-17 2018-11-15 Dow Agrosciences Llc 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
US20180370946A1 (en) * 2015-11-17 2018-12-27 Dow Agrosciences Llc 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
JP6928096B2 (ja) * 2017-01-10 2021-09-01 イーティーエイチ・チューリッヒ 細胞保護化合物及びそれらの使用
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
WO2024033677A1 (en) * 2022-08-09 2024-02-15 Faculdade De Farmácia Da Universidade De Lisboa One-pot method for the synthesis of 3-acetamido-furfural from n-acetylglucosamine
JP7356203B1 (ja) * 2023-08-03 2023-10-04 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 ＷＤ ａｎｄ ｔｅｔｒａｔｒｉｃｏｐｅｐｔｉｄｅ ｒｅｐｅａｔｓ １遺伝子発現亢進用医薬組成物及び食品組成物
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DK337086A (da) * 1985-08-12 1987-02-13 Hoffmann La Roche Benzimidazolderivater
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US20020032330A1 (en) * 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
JPH10306076A (ja) 1997-03-06 1998-11-17 Nippon Chemiphar Co Ltd プロピオン酸誘導体
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20020060067A (ko) * 1999-04-06 2002-07-16 가와무라 요시부미 α-치환 카르복실산 유도체
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
DE60117059T2 (de) * 2000-12-06 2006-10-26 F. Hoffmann-La Roche Ag Kondensierte heteroaromatische glucokinaseaktivatoren
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2004123711A (ja) * 2002-08-02 2004-04-22 Sankyo Co Ltd レゾルシノール誘導体
WO2004013109A1 (ja) 2002-08-02 2004-02-12 Sankyo Company, Limited レゾルシノール誘導体
JP2004067629A (ja) * 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
US7728025B2 (en) 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative

Also Published As

Publication number Publication date
IL182679A0 (en) 2007-09-20
NZ554440A (en) 2010-01-29
WO2006049304A1 (ja) 2006-05-11
EP1810969A1 (en) 2007-07-25
RU2398773C2 (ru) 2010-09-10
MX2007005289A (es) 2007-07-19
CN101094847B (zh) 2011-06-15
RU2007120519A (ru) 2008-12-10
EP1810969B1 (en) 2013-08-07
BRPI0517232A (pt) 2008-10-07
MA29043B1 (fr) 2007-11-01
CR9078A (es) 2007-10-01
JP5036316B2 (ja) 2012-09-26
CA2586056A1 (en) 2006-05-11
CA2586056C (en) 2012-03-13
US7932394B2 (en) 2011-04-26
US20080125429A1 (en) 2008-05-29
CN101094847A (zh) 2007-12-26
AU2005301608A1 (en) 2006-05-11
KR20070083939A (ko) 2007-08-24
JPWO2006049304A1 (ja) 2008-05-29
ECSP077422A (es) 2007-05-30
EP1810969A4 (en) 2011-05-25
AU2005301608B2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
NO20072806L (no) Aryloksy-substituerte benzimidazolderivater
NO20066015L (no) Fuserte heterosykliske forbindelser
TW200736363A (en) Material for organic electroluminescent device and organic electroluminescent device
MXPA05008619A (es) Derivados novedosos de 2-piridincarboxamida.
NO20091793L (no) 2-pyridinkarboksamidderivat med GK-aktiverende virkning
MXPA05009059A (es) Derivados de heteroarilcarbamoilbenceno.
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
ECSP066682A (es) Derivado novedoso de bencimidazol 2-heteroaril-substituido
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20061076L (no) (Tio)karbamoylsykloheksanderivater som D3/D2 -reseptorantagonister
NO20064089L (no) Kondensert ring 4-oksopyrimidinderivat
NO20072632L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
MX2009010024A (es) Nuevo compuesto de adenina.
WO2005097129A3 (en) 6-azaindole compound
MY142807A (en) Benzimidazole derivative and use thereof.
TN2010000091A1 (en) Substituted pyrazole derivative
SG163617A1 (en) Macrocyclic inhibitors of hepatitis c virus
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
NO20090952L (no) N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav
TW200745118A (en) Macrocylic inhibitors of hepatitis C virus
MX2009006024A (es) Derivados de heteroaril piridopirimidona sustituidos.
TW200745032A (en) Novel heterobicyclic derivatives
NO20076624L (no) Syklisk aminderivat med substituert alkylgruppe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application